Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Oct 13, 2024 8:56am
149 Views
Post# 36264407

RE:EDEN Study

RE:EDEN Study

Agree money4golf !

As it is, Shareholders hear/see very little in the way of promotion, enthusiasm, etc. from Mgt.  Eden and Tigris results, good or bad, should be, at the very least, continually summarized & characterized for all, if known to some. 

The fact that Tigris was tracking/ mirroring Euphas 2 results is an important example of good, necessary and fair disclosure.  

I for one would not like to hear that business partners, insiders, potential tire-kickers, larger shareholders, etc. had access to material or more up to date information from EDEN and or Tigris, that small retail shareholders do not. 

Regarding the dropping of "exceeding expectations" descriptor for Tigris results (roughly around the beginning of 2024, for whatever reason) ... one can only reasonably conclude that (1) there has been no change to this characterization since, and (2) large transactors know no additional details ( eg magnitude or changes to characterizations ) that might influence their decisions to transact.  


MM 

<< Previous
Bullboard Posts
Next >>